Sandoz announces $300 million biosimilar factory in Slovenia and plans to expand pipeline sevenfold
Sandoz, the generic and biosimilar division of Novartis, said it will invest $300 million to build a new biosimilar manufacturing facility in Slovenia.
The company also announced that its newly created biosimilar unit will increase its product pipeline more than sevenfold, aiming to broaden its portfolio of affordable biologic medicines.
CEO Richard Saynor highlighted the move as part of a broader strategy to strengthen Sandoz’s position in the competitive biosimilar market and to meet growing demand for cost‑effective treatments.
The investment underscores Sandoz’s confidence in the European manufacturing hub and could create jobs in the region.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that